Wuxi Biologics: Plans to repurchase up to $400 million in shares
WuXi Biology has announced plans to repurchase up to $400 million of its stock. The company's board of directors approved the buyback, which will be executed on the open market over time. This move comes as spot gold prices have seen a slight decline. AI
IMPACT Company's financial maneuver has minimal direct impact on AI operations.